(Date:12/7/2009)... partners with Cure to support medical research. , ... ... its part to help find a cure for spinal cord injury: ... Catheters to its list of nearly 45,000 products., , ,Cure Medical ... facilitate finding a cure for spinal cord injury, the company donates ...
(Date:12/7/2009)... -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: ... St. George,s Hospital, University of London during a ... ("ASH") Annual Meeting updated results from the pivotal ... pixantrone (the "PIX 301 EXTEND trial") in relapsed ... who have failed 2 or more prior therapies. ...
(Date:12/6/2009)... BROOK, Ill., Dec. 7 The University ... (AMC) members for their achievements in UHC,s Supply ... organizations are noted for modeling best practices in ... http://www.newscom.com/cgi-bin/prnh/20091207/CG21708 ) ,, The winners were determined ... that includes contract portfolio participation and use of ...
(Date:12/6/2009)... that the loss of a key segment of DNA can ... to show that this kind of genetic alteration can cause ... , The study, led by Dr Sadaf Farooqi from the ... Trust Sanger Institute, looked at 300 children with severe obesity. ... types of mutation known as copy number variants (CNVs). CNVs ...
(Date:12/6/2009)... Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) today ... 2b 003-A1 study, known as the 003 trial, ... relapsed and refractory multiple myeloma patients. These data ... at the 51st annual meeting of the American ... in this trial is complete (n=269), and full ...
Breaking Medicine News(10 mins):Health News:Online Medical Supply Superstore Adds Cure Catheters to Product Mix 2Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 2Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 3Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 4Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 5Health News:Recognized Top Performers in UHC Supply Chain 2Health News:Genetic studies reveal new causes of severe obesity in childhood 2Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 2Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 3Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 4Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 5